Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Inclusion Criteria: * Age \>= 18 years * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 as defined * Confirmed diagnosis of unresectable stage IV metastatic melanoma involving the lungs (at least) that has progressed after at least ONE line of Food and Drug Administration (FDA) approved therapy (either immune checkpoint inhibitor or targeted therapy) OR relapse of melanoma following/during FDA-approved adjuvant or neo-adjuvant therapy * Hemoglobin \>= 8.0 g/dL (obtained =\< 15 days prior to registration) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 15 days prior to registration) * Platelet count \>= 75,000/mm\^3 (obtained =\< 15 days prior to registration) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (obtained =\< 15 days prior to registration) * Alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) =\< 3.0 x ULN (obtained =\< 15 days prior to registration) * Serum creatinine =\< 2.0 x ULN (obtained =\< 15 days prior to registration) * Calculated creatinine clearance \>= 40 ml/min using the Cockcroft-Gault formula (obtained =\< 15 days prior to registration) * Pulse oximetry at rest \> 90% without use of supplemental oxygen * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only * Persons able to become pregnant OR able to father a child must be willing to use an a…